Introduction
Lung cancer is a major cause of mortality worldwide, and it is the leading cause of cancer death in the United States (Landis et al., 1998) . There were 171 500 new cases of lung cancer diagnosed and 160 100 deaths in 1998, making lung cancer a major health problem in this country. The constitutive activation or overexpression of proto-oncogenes and the inactivation of tumor suppressor genes are critical in the multistep process of lung carcinogenesis. These oncogenic changes are not only present in lung tumors, but some can already be detected in the nonmalignant bronchial epithelium of current and former smokers (Wistuba et al., 1997) . A number of proto-oncogenes have been shown to be altered in non-small cell lung cancer (NSCLC) including RAS, MYC, HER2/NEU, MYB, RAF and JUN (Fong et al., 1995) . Lung cancer also demonstrates loss of imprinting (LOI) at the insulin-like growth factor II (IGF2) locus (Suzuki et al., 1994) resulting in the biallelic expression of a growth factor known to be oncogenic when overexpressed (Bates et al., 1995; Rogler et al., 1994) . Tumor suppressor genes mutated in NSCLC include p53, Rb, p16INK4A and FHIT (Sekido et al., 1998) . The presence of deletions at numerous other chromosomal locations in NSCLCs, however, suggests the presence of additional lung tumor suppressor genes.
The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) is located at 6q26, a chromosomal location commonly deleted in NSCLCs (Bepler and Koehler, 1995; Petersen et al., 1997) . It encodes for a multifunctional receptor required for the activation of the growth inhibitor, transforming growth factor b1 (TGFb1), the degradation of the mitogen, IGF2, and the intracellular sorting of lysosomal enzymes (Dennis and Rifkin, 1991; Kornfeld, 1992; Jirtle, 1999a) . Evidence to date suggests, however, that the M6P/ IGF2R is not involved in cell signaling (Korner et al., 1995) ; this function is mediated primarily by the insulin-like growth factor I receptor (IGFIR) and the insulin receptor isoform A (Czech et al., 1989; Frasca et al., 1999) . The M6P/IGF2R has also been shown to be mutated in a number of human cancers, including those that develop in the liver, breast and colon (Jirtle et al., 1999b) , and to suppress cancer cell growth (Kang et al., 1999; O'Gorman et al., 1999; Souza et al., 1999) . These ®ndings are consistent with the M6P/ IGF2R functioning normally as a tumor suppressor.
The purpose of this investigation was to determine if the M6P/IGF2R is a gene target for mutation in human lung cancer, a disease strongly associated with tobacco smoking. Herein, we report that the M6P/ IGF2R is mutated in approximately 60% of squamous cell carcinomas of the lung, a mutation frequency comparable to that of p53 in lung cancer (Sekido et al., 1998) .
Results and discussion
There are two mannose 6-phosphate receptors involved in the intracellular tracking of lysosomal enzymes, the 46 kDa cation-dependent mannose 6-phosphate receptor (CDM6PR) and the 275 kDa cation-independent M6P/IGF2R (Kornfeld, 1992; Jirtle, 1999a) . In contrast to the CDM6PR, the M6P/IGF2R also binds extracellular phosphomannosyl glycoproteins and IGF2 when located at the cell surface. Thus, in addition to the intracellular sorting of lysosomal enzymes, the M6P/IGF2R controls the extracellular levels of potent growth factors and proteolytic enzymes that govern cell death, proliferation and invasion (Kornfeld, 1992; Jirtle, 1999a ).
The earliest experimental evidence for the involvement of the M6p/Igf2r in tumor formation came from rat liver carcinogenesis studies (Jirtle et al., 1994) . A small subset of diethylnitrosamine initiated, phenobarbital promoted preneoplastic liver lesions failed to stain immunohistochemically for the M6p/Igf2r while the majority of hepatocellular carcinomas were either partially or uniformly negative for this receptor. This demonstrated that loss of M6p/Igf2r function occurs early in rat liver carcinogenesis, and suggested that preneoplastic lesions lacking this receptor preferentially progress to carcinomas.
M6P/IGF2R inactivation has also now been demonstrated in human tumors. LOH at the M6P/IGF2R locus occurs in 60% of human HCCs (De Souza et al., 1995a; De Souza et al., 1995b; Yamada et al., 1997) and 30% of breast cancers (Hankins et al., 1996) , and missense mutations that reduce receptor function have been identi®ed in the remaining allele Yamada et al., 1997; Byrd et al., 1999; . The M6P/IGF2R also contains a poly-G region that is a common target for frame-shift mutations in colon, gastric, endometrial and liver tumors with mismatch repair de®ciencies and microsatellite instability (MI) (Ouyang et al., 1997; Yamada et al., 1997) . Moreover, the M6P/ IGF2R is mutated in human gliomas that do not contain mutations in the TGFb type II receptor or Bax genes (Leung et al., 1998) .
Induction of exogenous wild-type M6P/IGF2R in human colorectal cancer cells with an inactivated allele signi®cantly decreases growth rate and enhances apoptosis . In contrast, receptor down-regulation in choriocarcinoma cells by antisense M6P/IGF2R RNA increases both tumor cell growth rate and tumorigenicity (O'Gorman et al., 1999) . The M6P/IGF2R also contains a retinoic acid (RA) bind site (Kang et al., 1997) , and receptor overexpression in RA-resistant cancer cells lacking functional RA nuclear receptors confers susceptibility to RA-induced apoptosis (Kang et al., 1999) . The results of these functional studies, coupled with frequent M6P/IGF2R mutation in a number of human cancers, demonstrate the importance of this genetic target in human carcinogenesis.
To determine if the M6P/IGF2R is mutated in squamous cell carcinoma of the lung, we screened 22 patients for LOH at this locus. Of these 22 patients, 19 (86%) were informative (heterozygous) for a polymorphic dinucleotide repeat sequence and a tetranucleotide insertion/deletion polymorphism located in the 3'-untranslated region of the receptor (Hol et al., 1992) (Figure 1 ). There were six female and 13 male patients in the informative group. The average age of these patients was 65+ 3 years, and they all had a history of smoking (Table 1 ). LOH at the M6P/IGF2R locus was observed in 11/19 (58%) informative patients. The average age of the patients in the tumor LOH group (66+3 years) was not signi®cantly dierent (P40.1) from that in the tumor non-LOH group (63+5 years). The tumor stage also did not vary signi®cantly between these two tumor groups with most patients being either stages 3a or 3b (Table 1) .
Although there is signi®cant sequence homology between the extracellular region of CDM6PR and all 15 repeat domains in the M6P/IGF2R, only repeat domains 3 and 9 contain an M6P binding site (Dahms et al., 1987 (Dahms et al., , 1993 Lobel et al., 1988) . The minimal binding region for IGF2 in the human receptor is located in the N-terminal portion of repeat 11 (Dahms et al., 1994; Garmroudi et al., 1996; Schmidt et al., 1995) , and repeat 13 further enhances the IGF2 binding anity of the M6P/IGF2R (Devi et al., 1998) . The mannose 6-phosphate binding sites and the IGF2 binding and enhancing regions of the M6P/ IGF2R gene were screened for mutations in the tumors with LOH. Mutations were detected in these receptor binding regions in 6/11 (55%) tumors (Figure 2 ). The codon changes, amino acid changes and the predicted changes in secondary protein structure resulting from these mutations are presented in Table 2 .
No mutations were identi®ed in exons 8 to 11 indicating that the M6P binding site present in repeat 3 is not commonly mutated in squamous cell carcinomas of the lung. In contrast, 2/11 lung tumors were mutated in the M6P binding domain contained in repeat 9. A G:C?C:G transversion was identi®ed at a non CpG site in exon 27 that results in the substitution of Arg for Gly1296 (Figure 2a ). This amino acid is conserved among human, bovine, rat, mouse and chicken indicating that Gly1296 is important for receptor function. The secondary structure of this repeat region has been modeled on the 3-D structure of the CDM6PR which forms a nine stranded¯attened b barrel (Roberts et al., 1998) . Based upon this predicted secondary structure, Gly1296 of repeat 9 resides in the loop region between beta strands 4 and 5, the transition region between the two orthogonal b sheets. Therefore, the substitution of Arg, a large charged amino acid, for Gly1296, a small neutral amino acid, would be expected to signi®cantly alter the interaction between the two beta sheets thereby reducing receptor function.
The second mutation identi®ed in repeat 9 is a G insertion into the M6P/IGF2R poly-G region of exon 28 ( Figure 2b ). This single base frameshift mutation results in the formation of the stop codon TAA for Lys1321, thereby inhibiting the production of a functional receptor as previously shown by immunohistochemistry . The poly-G region in the M6P/IGF2R gene is a target of MI in replication/repair error-positive (RER+) endometrial, stomach and colorectal tumors (Ouyang et al., 1997; Figure 1 Representative M6P/IGF2R informative patients (a,b) without LOH (a) and with LOH (b) in human squamous cell carcinomas of the lung. A non-informative lung cancer patient is also shown (c). Alleles are de®ned as A1 and A2 for the informative patients and A1/A2 for the non-informative patient. Arrowhead marks the lost allele; faint band due to contaminating normal stromal tissue and/or PCR artifact Souza et al., 1996) , and it is also mutated in approximately 25% of hepatocellular carcinomas . A deoxyguanine insertion into the poly-G region of the M6P/IGF2R indicates this region may also be a target of MI in squamous cell carcinomas of the lung. Our ®nding contradicts the recent reported absence of mutations in the poly-G region of the M6P/IGF2R in lung tumors (Gotoh et al., 1999) . This most likely results from the inclusion of RER+ tumors with MI in our study population, even though its frequency appears to be low in lung cancer (Sekido et al., 1998) .
Three dierent missense mutations were also detected in repeat domain 11 that contains the IGF2 binding site, but no mutations were found in the IGF2 binding enhancer site present in repeat domain 13 (exons 37 ± 39) (Devi et al., 1998) . A G:C?C:G transversion was identi®ed at a non CpG site in exon 33 that results in the substitution of Arg for Gly1564 (Figure 2c ). This amino acid alteration occurs within the identi®ed minimal IGF2 binding site (Dahms et al., 1994; Garmroudi et al., 1996; Schmidt et al., 1995) , and is predicted from the 3-D structure of the CDM6PR to be in a putative loop region between beta strands 2 and 3 (Roberts et al., 1998) . The substitution of Arg, a large charged amino acid, for Gly1564, a small neutral amino acid, would be expected to signi®cantly alter receptor tertiary structure and function. Additionally, Gly1564 is conserved among mammalian species, but it is mutated in the chicken. This provides further evidence that Gly1564 plays a signi®cant role in binding IGF2 since unlike the mammalian M6P/IGF2R homologues, the chicken receptor does not bind IGF2 (Zhou et al., 1995) .
The second mutation detected in repeat domain 11 of the M6P/IGF2R is a G:C?A:T transition at a non CpG site in exon 34 that results in the substitution of Thr for Ala1618 (Figure 2d ). This amino acid change is predicted from the 3-D structure of the CDM6PR to reside in a putative loop region between beta strands 7 and 8 (Roberts et al., 1998) . The substitution of Thr, an uncharged polar amino acid, for Ala1618, a nonpolar hydrophobic amino acid, would be expected to aect the receptor tertiary structure and function since the interactions between the two orthogonal beta sheets is principally hydrophobic in nature (Roberts et al., 1998) . The hydrophobic interactions between the beta sheets makes the overall structure very tight and compact. An alteration in the receptor compactness may not only reduce IGF2 binding but also receptor half-life since it resides part of the time in the proteolytic environment of the lysosomes (Kornfeld, 1992) . Ala1618 is also conserved among human, rat, mouse and chicken suggesting that this amino acid plays an important role in the function and/or stability of the receptor. The third mutation detected in repeat domain 11 of the receptor is a G:C?A:T transition at a CpG site in exon 34 that results in the substitution of Arg for Gly1619 (Figure 2e,f) . This amino acid alteration is also predicted from the 3-D structure of the CDM6PR to reside in a putative loop region between beta strands 7 and 8 (Roberts et al., 1998) . The substitution of Arg, a large charged amino acid, for Gly1619, a small neutral amino acid, would be expected to signi®cantly alter receptor tertiary structure and function. Gly1619 is conserved among bovine, human, mouse, rat and chicken. Furthermore, this mutation was detected in two lung tumors highly suggesting that this amino acid is important in maintaining receptor function and/or stability.
The presence of mutations in both the M6P binding site in repeat 9 and the IGF2 binding site in repeat 11 suggests that both phosphomannosyl containing glycoproteins and IGF2 are involved in the etiology of lung cancer. Additionally, every M6P/IGF2R missense mutation detected in squamous cell carcinoma of the lung occurred within the predicted transition region between beta strands, and 80% of them involved Gly (Table 1) . Thus, these loop regions appear to be critical to receptor ligand binding function and/or its stability. This postulate is further supported by our recent ®nding that substitution of a Val for Gly1449 in a putative loop region of repeat 10 markedly reduces receptor binding of both IGF2 and M6P containing ligands Devi et al., 1999) .
We also screened M6P/IGF2R for the G:C?T:A transversion in exon 31 that results in the substitution of a Val for Gly1449. Although this mutation is present in 13% of HCCs (De Souza et al., 1995b; Yamada et al., 1997) , it was not detected in squamous cell carcinoma of the lung. This is particularly interesting since carcinogens found in smoke such as benzo[a]pyrene diol epoxide preferentially attack deoxyguanine, frequently resulting in a G:C?T:A transversion (Greenblatt et al., 1994) . Furthermore, none of the M6P/IGF2R missense mutations found in squamous cell carcinomas of the lung have been detected in either HCCs or breast cancer (De Souza et al., 1995b; Hankins et al., 1996; Yamada et al., 1997) . Thus, the M6P/IGF2R mutational spectrum appears to be tumor speci®c and/or dependent upon the carcinogenic agent involved in the etiology of tumor formation.
M6P/IGF2R immunohistochemical staining was absent in the six squamous cell carcinomas of the lung in which both alleles of the gene were found to be mutated, but was present in tumors without LOH (Figure 3) . The lack of immunohistochemical staining in tumors harboring not only frameshift but also missense mutations could result from structural changes in the receptor altering the primary epitopes recognized by the M6P/ IGF2R antibody. Alternatively, receptors with reduced compactness because of missense mutations could have an enhanced susceptibility to proteolytic degradation when they reside in the lysosomes, thereby reducing the steady-state receptor level below that which is detectable. This latter postulate is supported by our recent ®nding that receptor stability in vitro is decreased by a missense mutation in repeat 10 of the M6P/IGF2R Devi et al., 1999) . We further observed that the (Tables 1 and 2 , Patient 1); the adjacent normal connective tissue (N) was slightly stained. Control rabbit IgG staining was negative (data not shown). Tissues were counterstained with hematoxylin, X500 Killian and Jirtle (1999) . b Based on Morgan et al. (1987) .
c Based on the 3D structure of the CDM6PR (Roberts et al., 1998) Oncogene M6P/IGF2R mutation in lung cancer F-M Kong et al majority of tumors with LOH at the M6P/IGF2R locus (10/11) lack detectable receptor protein even though the remaining allele is not mutated in the receptor binding regions. This could result from the allele being mutated in gene regions not screened in this investigation. Gene expression could also be inhibited by epigenetic alterations, as occurs frequently with p16INK4A in lung cancer (Gazzeri et al., 1998) . Additionally, one allele of the M6P/IGF2R could be transcriptionally silenced in lung tumors because of imprinting. Genomic imprinting is an epigenetic form of gene regulation that results in the expression of only one parental allele, and a number of imprinted genes have been determined to be oncogenic targets (Falls et al., 1999; . The M6p/Igf2r gene is imprinted in both mice (Barlow et al., 1991; Wang et al., 1994) and rats (Mills et al., 1998) , whereas imprinting of the M6P/IGF2R is a polymorphic trait in humans with most adults expressing both alleles (Falls et al., 1999; . Thus, imprinting of the M6P/IGF2R could result in allelic inactivation, a postulate supported by the discovery that 50% of patients with Wilms' tumor are imprinted at this locus (Xu et al., 1997) . Unfortunately, it was not possible to determine if M6P/IGF2R was imprinted in these lung tumors because RNA could not be isolated from the formalin ®xed, paran embedded tissues.
Although radiographic techniques have improved the detection of small lung tumors, 90% of lung cancer patients still die of their disease because of a propensity for lung cancer to metastasize early. For those patients in whom NSCLC is detected at an early stage, the 5 year survival following surgery exceeds 60% (Landis et al., 1998) . The cure rates exceed 90% with surgical resection for patients with truly occult NSCLC (i.e., asymptomatic, fortuitously discovered lesions not visible on X-ray) (Ginsberg et al., 1997) . Thus, while eective treatment exists for early stage NSCLC, to date there remains no widely accepted screening intervention for this disease (Rimer and Schildkraut, 1997) . Since M6P/IGF2R mutation is an early event in liver and breast carcinogenesis (Chappell et al., 1997; Hankins et al., 1996) , it may provide an important molecular marker for early neoplastic changes in the lung. The vast majority of lung cancers are smoking related, and the ability to detect early lesions in this high risk population could save over 100 000 lives per year in the United States alone (Landis et al., 1998) .
In conclusion, M6P/IGF2R mutation is a frequent occurrence in squamous cell carcinoma of the lung, indicating that it normally functions as a lung tumor suppressor gene. Additional studies are required to determine if M6P/IGF2R mutation is an early event in lung carcinogenesis, and if gene loss alters patient prognosis.
Materials and methods

Patients
Archival paran embedded tissue sections from 22 randomly selected patients with histopathologically con®rmed squamous cell carcinoma of the lung were obtained from the Department of Pathology, Duke University Medical Center.
All patients were treated between 1992 and 1995, and had a history of smoking.
Tissue microdissection from paraffin embedded sections
Microdissection of tumor and normal tissue from 6 mm histology sections was performed as previously described (De Souza et al., 1995a; Hankins et al., 1996) . Normal stroma not immediately adjacent to cancer cells was used as the control tissue. The areas chosen for microdissection were identi®ed by a board-certi®ed pathologist (MK Washington) who also classi®ed the lesions. Paran embedded sections were deparanized in xylene (265 min), placed in 100% ethanol (265 min) followed by 50% ethanol (265 min) and then rehydrated in H 2 O prior to staining. The tissue sections were stained for 30 s with 2% (w/v) methylene blue, rinsed in H 2 O and allowed to air dry. Tumor and normal tissue (450 cells) were then dissected and put in 50 ml of 16 PCR buer (10 mM Tris.HCl, pH 8.3 at 258C, 50 mM KCl) containing 2 ml of 20 mg/ml proteinase K (Roche Boehringer Mannheim, Indianapolis, IN, USA). The mixture was ®rst incubated at 568C for 60 min and then at 1008C for 10 min. 5 ± 10 ml of this mixture were used in the PCR analysis described below.
PCR analysis for loss of heterozygosity
Two polymorphisms are present in the 3'-untranslated region of the human M6P/IGF2R (Hol et al., 1992) . There is a tetranucleotide insertion/deletion close to a dinucleotide repeat which together give observed heterozygosity of approximately 60%. We utilized these polymorphisms to determine, by PCR ampli®cation of DNA, the frequency of LOH at the M6P/IGF2R locus in patients with squamous cell carcinomas of the lung. The forward and reverse PCR primers used were JJMIF (5'-TTGCCGGCTGGTGAATT-CAA-3') and JJMIR (5'-CTCTTCAGGTTCTCATGATA-3'), respectively (De Souza et al., 1995a) . The reaction conditions for PCR were as follows: 10 mM Tris.HCl, pH 8.3 at 258C, 50 mM KCl, 1 mM MgCl 2 , 200 mM 4dNTP mix, 200 nM forward and reverse primers, 5 ml microdissected template and 2.5 units Taq DNA polymerase (PE Biosystems, Foster City, CA, USA) in a total volume of 100 ml. Hot-start PCR was carried out under the following conditions: 1 min denaturing at 948C, 1 min annealing at 558C and 1 min extension at 728C for 30 cycles with an additional 10 min extension for cycle 30 on a DNA thermal cycler. The DNA generated by PCR was characterized by agarose gel electrophoresis and dideoxy sequencing.
Excess primers were removed using a Qiagen PCR puri®cation kit (Qiagen, Valencia, CA, USA). 10 ml of puri®ed PCR products were digested with 10 units EcoRI, and then labeled with a-33 P ATP (2000 Ci/mmol, 10 mCi/ml) using 2.5 units of Large Fragment DNA Polymerase I. Sequencing gel-loading buer [95% (v/v) deionized formamide, 20 mM EDTA (pH 8.0), 0.05% (w/v) xylene cyanol FF, and 0.05% (w/v) bromophenol blue] was added to the labeled PCR products in a ratio of 1 : 1 prior to heat denaturation (808C for 3 min) and electrophoresis was performed with a 6% denaturing polyacrylamide sequencing gel. The electrophoretic products were visualized by autoradiography. Due to the potential of contamination from normal stromal tissue, allele loss in informative patients was de®ned as a 450% decrease in the ratio of the two alleles in the tumor tissue versus that in the surrounding normal stromal tissue; this was quanti®ed using a densitometer.
M6P/IGF2R mutation detection
In lung tumors with LOH at the M6P/IGF2R locus, the remaining allele was screened for mutations in the ligand binding regions by direct sequencing of PCR products. The regions screened for mutations were exons 8 ± 11 (repeat 3), exons 27 ± 29 (repeat 9), exon 31 (repeat 10), exons 33 and 34 (repeat 11) and exons 37 ± 39 (repeat 13) (Killian and Jirtle, 1999) . Because Taq DNA polymerase can introduce base errors during the PCR process, a number of precautions were taken to address this potential problem. Mutant DNA templates were ampli®ed in two or more independent PCR reactions. The corresponding normal template, comprized of normal stromal tissue distant from the cancer cells, was always ampli®ed in parallel with the tumor template, and the tumor mutations were con®rmed by direct sequencing in both directions. Additionally, the genomic DNA was ampli®ed using nested primers. The ®rst round primers were removed using a Qiagen gel ®ltration kit (Clontech, Palo Alto, CA, USA), and 5 ml of the elute were used in a second round ampli®cation. Gel puri®ed second round PCR products were directly sequenced using the AmpliCycle TM kit (PE Biosystems, Foster City, CA, USA) and the second round primers. The exon speci®c forward and reverse PCR primers used have been previously published (http://www.geneimprint .com) (Killian and Jirtle, 1999) .
M6P/IGF2R immunohistochemical staining
The technique used to immunohistochemically detect M6P/ IGF2R protein in formalin ®xed, paran embedded tissues sections was modi®ed from Jirtle et al. (1994) . Following tissue section deparanization and hyaluronidase digestion, the 6 mm sections were blocked with protein solution (BioGenex, San Ramon, CA, USA) and exposed overnight at 48C to the C-1 rabbit polyclonal antibody to M6P/IGF2R (Scott and Baxter, 1987) ; non-immune rabbit IgG was used as a control. The tissue sections were then processed according to the recommended procedures provided with the Multilink-Alkaline Phosphatase Detection Kit (BioGenex, San Ramon, CA, USA). The alkaline phosphatase-containing Fast Red Tablet Kit (BioGenex, San Ramon, CA, USA) was used to immunohistochemically stain the tissues, and levamisole was applied to block endogenous alkaline phosphatase activity. All the tissue sections were counterstained with hematoxylin. Aqueous mounting media was used to cover the immunohistochemically stained slides.
